Phase 3 Trial on Oral Peanut Immunotherapy Shows Promise in Children and Adolescence.

Posted on: 12 December, 2018

A recent phase 3 trial on oral peanut immunotherapy suggests positive results and is one step closer to FDA approval.

This study was recently published in The New England Journal of Medicine. It showed that 67.2% of patients between ages 4 and 17 years old were able to ingest a dose of 600 mg or more of peanut protein after receiving the active treatment, AR101, compared to 4% of patients who received the placebo. This effect was not seen in patients 18 years or older.

Currently, this therapy is on the “fast-track” for approval by the F.D.A. Although this is not a cure for peanut allergy, this may prevent a severe reaction after accidental ingestion. A link to the article is below:

https://www.nejm.org/doi/10.1056/NEJMoa1812856

Make sure to follow and like us on social media including facebook, twitter and instagram to get the latest breaking news in allergy and immunology.

Conditions Treated

Allergy Shots

Allergy immunotherapy, also called “allergy shots,” is prescribed to modify the immune system’s response to allergens with the goal of minimizing and/or preventing an allergen initiated inflammatory response.
Allergy Drops & Tablets

Allergy drops, and tablets are two forms of sublingual immunotherapy that are injection-free alternatives to allergy shots. Both contain environmental allergen such as pollen, dust mites, molds, cat, or dog.
Asthma

Asthma is a chronic inflammatory lung condition that usually starts in childhood but can occur at any age. Allergists are considered the experts in asthma and diagnose this condition by history, exam and breathing tests of the airways.
Allergy & Sinus

Allergic rhinitis is one of the most common chronic conditions in the US. Individuals with allergic rhinitis develop allergy antibodies (IgE) targeted against allergens including pollen, animal proteins, dust mites, mold, and insect droppings.
Food Allergy

Food allergy affects 5% of children and 4% of adults in the United States and is defined as an adverse health event that is immune mediated and occurs reproducibly. Individuals with IgE mediated food allergy develop allergy antibodies (IgE) targeted against food allergens.
Allergic Rashes

Atopic dermatitis is a chronic, relapsing inflammatory skin disorder that usually starts at age < 5 years. It is characterized by itchy skin that becomes inflamed with scratching. For this reason, atopic dermatitis is known as the “itch that rashes.”
Other Conditions